JADE BIOSCIENCES, INC.
NASDAQ: JBIO (Jade Biosciences, Inc.)
最近更新时间: 3小时之前21.51
-0.30 (-1.38%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 看涨 |
| Biotechnology (全球的) | 看涨 | 看涨 | |
| 股票 | Jade Biosciences, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -3.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -1.00 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.04% |
| 机构持股比例 | 33.40% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Fairmount Funds Management Llc | 31 Mar 2026 | 4,553,494 |
| Bellevue Group Ag | 31 Mar 2026 | 3,501,502 |
| Venrock Adviser, Llc | 31 Mar 2026 | 3,220,364 |
| Baker Bros. Advisors Lp | 31 Mar 2026 | 1,641,137 |
| Remedium Capital Partners, Llc | 31 Mar 2026 | 1,577,750 |
| Versant Venture Management, Llc | 31 Mar 2026 | 1,525,820 |
| Avidity Partners Management Lp | 31 Mar 2026 | 1,400,708 |
| Samsara Biocapital, Llc | 31 Mar 2026 | 968,798 |
| Great Point Partners I Lp | 31 Mar 2026 | 964,462 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合